New drug trial offers hope for kids whose cancers came back
NCT ID NCT02932280
Summary
This study is testing a drug called neratinib in children and young adults whose solid tumors, brain tumors, lymphoma, or leukemia have returned or did not respond to standard treatments. The main goals are to find a safe dose and see what effects, both good and bad, the drug has on the cancer and the patient. It is for participants aged 3 to 21 who have tried at least one prior therapy with no success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alberta Children'S Hospital
Calgary, Alberta, T3B 6A8, Canada
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72206, United States
-
Arnold Palmer Hospital for Children
Orlando, Florida, 32806, United States
-
Huntsman Cancer Institue
Salt Lake City, Utah, 84113, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Pennsylvania State Hershey Children's Hospital
Hershey, Pennsylvania, 17033, United States
-
Phoenix Children'S Hospital
Phoenix, Arizona, 85016, United States
-
Stanford University School of Medicine and Stanford Cancer Institute
Palo Alto, California, 94304, United States
-
University of Texas
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.